SPDR S&P Biotech (XBI)

Add to Watchlists
Create an Alert
247.02 -2.20  -0.88% NYSE Arca Jul 2, 4:59PM Delayed 2m USD
View Full Chart
XBI Price Chart

XBI Description

SPDR S&P Biotech is a long only equity fund managed by SPDR State Street Global Advisors that tracks the S&P Biotechnology Select Industry TR USD index and has 2.595B USD assets under management. It has an forecasted dividend yield of 0.03%, a forecasted PE ratio of 34.75, and a forecasted price to book value of 5.851. The fund has a net expense ratio of 0.35%, turns over its positions 86.00% per year, and is traded on the New York Stock Exchange Arca.

XBI Key Info

Expense Ratio (2-3-15) 0.35%
Assets Under Management (6-29-15) 2.595B
30-Day Average Volume (7-1-15) 1.124M
Net Asset Value (6-29-15) 241.39
Discount or Premium to NAV (6-29-15) 0.10%
Turnover Ratio (6-30-14) 86.00%

XBI Asset Allocation

Type % Net % Long % Short
Cash 0.05% 0.05% 0.00%
Stock 99.95% 99.95% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of June 29, 2015

XBI Region Exposure

Americas 98.93%
North America 98.93%
Latin America 0.00%
Greater Europe 1.07%
United Kingdom 0.00%
Europe Developed 1.07%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.0%
% Emerging Markets 0.00%
As of June 26, 2015
Region breakdown data is calculated by using the long position holdings of the portfolio.

XBI Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of June 29, 2015

XBI Stock Market Capitalization

Giant 3.90%
Large 4.96%
Medium 14.86%
Small 33.32%
Micro 42.91%
As of June 29, 2015
View More Holdings

XBI Top 10 Holdings

Name % Weight Price % Chg
KYTHERA Biopharmaceuticals Inc 1.34% 74.90 -0.25%
Radius Health Inc 1.25% 67.92 +1.46%
ZIOPHARM Oncology Inc 1.19% 11.23 -3.36%
Novavax Inc 1.15% 10.89 -1.00%
Biocryst Pharmaceuticals Inc 1.11% 15.10 +3.71%
MiMedx Group Inc 1.11% 10.86 -1.54%
Ultragenyx Pharmaceutical Inc 1.09% 102.78 -1.04%
Chimerix Inc 1.07% 46.10 +0.66%
Prothena Corp PLC 1.07% 50.64 -0.26%
Anacor Pharmaceuticals Inc 1.07% 78.62 -1.47%
As of June 29, 2015
Advertisement

XBI Basic Info

Style
Equity Style Small Cap/Growth
Broad Asset Class Sector Equity
Broad Category Equity
Prospectus Objective Specialty - Health
Fund Owner Firm Name SPDR State Street Global Advisors
Benchmark Index
S&P Biotechnology Select Industry TR USD 100.0%

XBI Manager Info

Name Tenure
John Tucker 9.25 yrs
Karl Schneider 0.50 yrs
Michael Feehily 3.50 yrs

XBI Risk Info

Beta 1.070
Max Drawdown (All) 37.69%
Historical Sharpe (10y) --
Historical Sortino (All) 1.431
30-Day Rolling Volatility 24.82%
Daily Value at Risk (VaR) 1% (All) 4.61%
Monthly Value at Risk (VaR) 1% (All) 19.40%

XBI Fundamentals

Dividend Yield TTM (7-2-15) 0.70%
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio 12.22
Weighted Average Price to Book Ratio 6.862
Weighted Median ROE -23.07%
Weighted Median ROA -22.40%
Forecasted Dividend Yield 0.03%
Forecasted PE Ratio 34.75
Forecasted Price to Sales Ratio 4.490
Forecasted Price to Book Ratio 5.851
Number of Holdings 104
As of June 29, 2015

XBI Growth Estimates

Forecasted 5 Yr Earnings Growth 17.02%
Forecasted Book Value Growth 10.17%
Forecasted Cash Flow Growth 11.87%
Forecasted Earnings Growth 16.33%
Forecasted Revenue Growth 5.41%
As of June 29, 2015

XBI Performance

  Returns Total Returns
1M 3.34% 3.52%
3M 11.88% 12.07%
6M 32.48% 32.85%
1Y 57.66% 59.07%
3Y 179.2% 184.6%
5Y 388.5% 398.0%
As of June 29, 2015

XBI Net Flows

1M 8.205M
3M 76.14M
6M 473.74M
YTD 435.94M
1Y 505.57M
3Y 587.53M
5Y 521.83M
As of May 31, 2015

XBI Attributes

Key Dates
Inception Date 1/31/2006
Last Annual Report Date 6/30/2014
Last Prospectus Date 2/3/2015
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 7-Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.